Corcept Therapeutics
- Market cap
- 12.93B
- P/E (TTM)i
- 265.78
- P/Bi
- 18.32
- EPSi
- 0.82
- Div yieldi
- 0.00%
- 52W posi
- 93%
Anonymous reader poll. Unscientific, not investment advice.
Corcept Therapeutics ended the session at 119.60, little changed. At current prices, the business is worth about 12.93B, the #1285 most valuable US-listed company we track. Trading at a P/E of 252.22, the stock is 363% above its own five-year norm of 54.53. Wall Street's 5-analyst consensus lands on Buy, with a price target averaging 141.00 (+18% from here). The shares sit 93% of the way up their 52-week range of 28.66 to 126.38.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 26% of the universe, above its 200-day average.
- Signal has read BUY for 2 months.
- Its last 6 Buy calls have averaged close to flat (-1%) three months out - no strong edge on this name specifically.
- Recent price momentum is +29.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 8.7% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation F
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 271.2x | Better than 2% |
| Forward P/E | 25.1x | Better than 29% |
| Price / Sales | 14.8x | Better than 8% |
| P/E vs own 5-yr range | 97th pctl | Better than 4% |
Growth B
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 23.7% | Better than 87% |
| Net income CAGR (3Y) | -0.6% | Better than 37% |
| Free cash flow CAGR (3Y) | 5.7% | Better than 43% |
Profitability B
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 98.3% | Better than 100% |
| Operating margin | 5.9% | Better than 22% |
| Net margin | 12.9% | Better than 56% |
| Return on equity | 14.8% | Better than 55% |
| Return on invested capital | 12.2% | Better than 64% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 29.8% | Better than 93% |
| 6-month return | 192.7% | Better than 99% |
| 12-month return (ex latest month) | 24.2% | Better than 60% |
| Distance below 52-week high | 3.4% | Better than 94% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.9x | Better than 81% |
| Debt to assets | 0.7% | Better than 97% |
| Interest coverage | 1,078.7x | Better than 99% |
| Free cash flow / net income | 142.3% | Better than 69% |
Analyst View C+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 80.0% | Better than 58% |
| Upside to average target | 15.5% | Better than 28% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 119.57
- Open
- 119.00
- Day range
- 117.23 - 122.00
- Avg price
- 119.98
- Volume
- 634.88K
- Turnover
- 76.17M
- Turnover ratei
- 0.66%
- Volume ratioi
- 0.69
- Amplitudei
- 3.99%
- 52-week rangei
- 28.66 - 126.38
Valuation
- P/Ei
- 145.85
- P/E (TTM)i
- 265.78
- P/Bi
- 18.32
- EPSi
- 0.82
- Book value / shi
- 6.53
- Net profit
- 88.64M
- Net assets
- 705.77M
Share structure
- Market cap
- 12.93B
- Float capi
- 11.54B
- Shares out
- 108.10M
- Float sharesi
- 96.48M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
5.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-19.10M net over the window
Short interest
- Shares short
- 9.35M
- % of floati
- 8.65%
- Days to coveri
- 9.91
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Corcept Therapeutics (CORT)?
Corcept Therapeutics last traded at 119.60. The quote on this page refreshes every few seconds while US markets are open.
What is Corcept Therapeutics's market cap?
About 12.93B.
What is the P/E ratio of Corcept Therapeutics?
The trailing twelve-month P/E is 265.78, above its own 5-year average of 54.53 — toward the top of its historical range (96.65% percentile). See the Valuation tab for the full history.
Does Corcept Therapeutics pay a dividend?
Corcept Therapeutics does not currently pay a regular dividend.
Is Corcept Therapeutics a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 141.00, which implies 17.9% upside from the current price. This is not investment advice.
What is Corcept Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Corcept Therapeutics a B (Buy). Twelve-month momentum in the top 26% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-08 06:36:38 · For reference only, not investment advice and not tailored to your situation.